Kinase inhibitor scaffolds and methods for their preparation

A compound having the following Formula:

• wherein
• R is selected from the group consisting of a 5- or 6-membered heteroaryl and a 9- or 10-membered 6,5- or 6,6-fused heteroaryl, containing from 1-4 nitrogen atoms, optionally substituted with 1-2 groups independently selected from the group consisting of hydrogen, C1-6alkyl, aryl, C1-6alkylaryl, C3-8cycloalkyl, heterocycle, heteroaryl, C1-6alkylhydroxy, C1-6alkoxy and NR4R4;
• R1 is a member selected from the group consisting of phenyl and benzyl, substituted on the aromatic ring with from 1-4 substituents independently selected from the group consisting of C1-6alkyl, C1-6alkoxy, C1-6alkylhydroxy, C1-6alkylamine, C1-6aminoalkyl, halo and heterocycle;
• L is selected from the group consisting of —O—, —NR2— and a bond;
• each R2 is independently a member selected from the group consisting of hydrogen and C1-4alkyl;
• R3 is independently a member selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, halogen and alkoxy groups;
• or
• R2 and R3 taken together form a 3-8 membered heterocyclic ring containing from 1-2 heteroatoms selected from the group consisting of N and O, optionally substituted with 1-2 members independently selected from the group consisting of C1-4alkyl, C1-4alkylhydroxy, C1-4alkoxy and C1-4alkylamine;
• R4, if present, is a member selected from the group consisting of optionally substituted alkyl, optionally substituted heteroalkyl and acyl groups;
• and
• all pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs thereof.